Callan JMB

Callan JMB Net Debt/Equity

The Net Debt to Equity Ratio of Callan JMB (CJMB) as of Oct 29, 2026 is -0.06. In the previous year, Net Debt to Equity Ratio was -0.38 — a change of -85.20% (higher).

Net Debt/Equity

-0.06

YoY

-85.20%

Last updated:

Net Debt to Equity Ratio of Callan JMB is 2025 -0.06 . Net Debt to Equity Ratio of Callan JMB was 2024 -0.38 . It decreases by -85.20% higher compared to the previous year.

The Callan JMB Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2022
-0.41 USD
Jan 1, 2023
-0.54 USD
Jan 1, 2024
-0.38 USD
Jan 1, 2025
-0.06 USD
The Callan JMB Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.06-85.20%
-0.38-30.62%
-0.54+31.01%
-0.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Callan JMB Stock analysis

What does Callan JMB do? Callan JMB Inc provides thermal management logistics solutions for the life sciences industry, including personalized medicine, cell therapies, and vaccines. The company's Ship2Q ultraviolet disinfection process ensures thermal reliability and cleanliness of packaging systems. Its vertically integrated model combines proprietary packaging, IT, and cold chain logistics expertise to serve clients requiring cryogenic or frozen shipping. The firm targets life sciences companies needing specialized shipping solutions for temperature-sensitive products. Callan JMB Inc's primary products include thermal management logistics services and the Ship2Q disinfection process. These solutions address the full range of frozen shipping needs in the life sciences sector. The company serves manufacturers of biopharmaceuticals, diagnostic materials, and other temperature-sensitive commodities. Its services ensure that shipping systems meet manufacturer specifications for fitness and thermal performance. The company's business model focuses on providing comprehensive alternatives to traditional logistics solutions for frozen shipping. It operates as a vertically integrated provider, handling all aspects of cold chain logistics from packaging to delivery. Callan JMB Inc's target clients are life sciences companies requiring reliable, temperature-controlled shipping for sensitive materials like cell lines, cord blood, and organs. The firm's proprietary technology differentiates it in the specialized logistics market. Callan JMB is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Callan JMB stock

Net Debt to Equity Ratio of Callan JMB is -0.06 in 2025.

Net Debt to Equity Ratio of Callan JMB changed from -0.38 to -0.06, representing a -85.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Callan JMB since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Callan JMB with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Callan JMB

All Key Metrics — Callan JMB